Literature DB >> 27757783

Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.

Aihua Xu1,2, Md Ahsanul Kabir Khan1, Fangzhi Chen3, Zhaohui Zhong3, Han-Chun Chen4, Yuanda Song5,6.   

Abstract

Autotaxin (ATX) as an important tumor cell motility-stimulating factor is upregulated in many different types of cancer. ATX, a member of the ectonucleotide pyrophosphatase and phosphodiesterase family of enzymes, possesses lysophospholipase D activity which hydrolyzes lysophosphatidylcholine to generate the potent tumor growth factor and mitogen lysophosphatidic acid (LPA). LPA acts on specific G-protein-coupled receptors, thereby regulating cell growth, migration, and survival. This study aimed to investigate the differences in gene expression pattern of ATX between cancerous and adjacent normal tissue of human renal cell carcinoma (RCC) and bladder carcinoma (BC) and find the correlation between ATX expression and clinicopathological features of both of these carcinomas. Both the RCC and BC tissues and with the adjacent normal tissues were collected. Immunohistochemistry and Western blotting analysis were used to detect the extent of ATX expression in all of these samples. Immunohistochemistry and Western blot analysis revealed that expression of ATX protein in carcinoma tissues is significantly higher than that in the adjacent normal tissues. Immunohistochemistry analysis showed that ATX is localized in cytoplasm. Western blotting analysis showed that ATX protein is expressed in both RCC and BC, and the expression levels were 69.5 and 48.0 %, respectively, higher in RCC and BC carcinoma tissue samples than in the adjacent normal tissues, which is consistent with the results of immunohistochemistry study. Thus, this study provided the evidence that ATX is highly expressed in both RCC and BC. Further research can be done to identify the diagnosis and treatment significance of both these carcinomas.

Entities:  

Keywords:  Autotaxin; Bladder carcinoma; Immunohistochemistry; Renal cell carcinoma; Western blotting

Mesh:

Substances:

Year:  2016        PMID: 27757783     DOI: 10.1007/s12032-016-0836-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

Review 1.  Autotaxin and LPA receptor signaling in cancer.

Authors:  Anna J S Houben; Wouter H Moolenaar
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 2.  Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions.

Authors:  Matthew G K Benesch; Yi M Ko; Todd P W McMullen; David N Brindley
Journal:  FEBS Lett       Date:  2014-02-19       Impact factor: 4.124

3.  The Global Burden of Cancer 2013.

Authors:  Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

Review 4.  Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases.

Authors:  R P Cholia; H Nayyar; R Kumar; A K Mantha
Journal:  Curr Mol Med       Date:  2015       Impact factor: 2.222

5.  Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.

Authors:  Laurens A van Meeteren; Paula Ruurs; Evangelos Christodoulou; James W Goding; Hideo Takakusa; Kazuya Kikuchi; Anastassis Perrakis; Tetsuo Nagano; Wouter H Moolenaar
Journal:  J Biol Chem       Date:  2005-03-15       Impact factor: 5.157

6.  Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.

Authors:  Adam J Stein; Gretchen Bain; Pat Prodanovich; Angelina M Santini; Janice Darlington; Nina M P Stelzer; Ranjinder S Sidhu; Jeffrey Schaub; Lance Goulet; Dave Lonergan; Imelda Calderon; Jilly F Evans; John H Hutchinson
Journal:  Mol Pharmacol       Date:  2015-09-14       Impact factor: 4.436

Review 7.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

Review 8.  Autotaxin: a protein with two faces.

Authors:  Mousumi Tania; Md Asaduzzaman Khan; Huaiyuan Zhang; Jinhua Li; Yuanda Song
Journal:  Biochem Biophys Res Commun       Date:  2010-10-01       Impact factor: 3.575

9.  Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization.

Authors:  M J Stassar; G Devitt; M Brosius; L Rinnab; J Prang; T Schradin; J Simon; S Petersen; A Kopp-Schneider; M Zöller
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

10.  A New Enzyme Immunoassay for the Quantitative Determination of Classical Autotaxins (ATXα, ATXβ, and ATXγ) and Novel Autotaxins (ATXδ and ATXε).

Authors:  Yasunori Tokuhara; Makoto Kurano; Satoshi Shimamoto; Koji Igarashi; Takahiro Nojiri; Tamaki Kobayashi; Akiko Masuda; Hitoshi Ikeda; Takeshi Nagamatsu; Tomoyuki Fujii; Junken Aoki; Yutaka Yatomi
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

View more
  12 in total

1.  Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.

Authors:  Sudeepti S Kuppa; Wei Jia; Shuying Liu; Ha Nguyen; Susan S Smyth; Gordon B Mills; Kevin K Dobbin; William J Hardman; Mandi M Murph
Journal:  Cancer Lett       Date:  2018-05-31       Impact factor: 8.679

2.  Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.

Authors:  Ya-Lan Dong; Xue-Yun Duan; Yu-Jin Liu; Heng Fan; Meng Xu; Qian-Yun Chen; Zhen Nan; Hui Wu; Shuang-Jiao Deng
Journal:  Inflammation       Date:  2019-10       Impact factor: 4.092

3.  Tetra-linoleoyl cardiolipin depletion plays a major role in the pathogenesis of sarcopenia.

Authors:  Richard D Semba; Ruin Moaddel; Pingbo Zhang; Christopher E Ramsden; Luigi Ferrucci
Journal:  Med Hypotheses       Date:  2019-04-17       Impact factor: 1.538

Review 4.  Lipids in the tumor microenvironment: From cancer progression to treatment.

Authors:  Kevin C Corn; McKenzie A Windham; Marjan Rafat
Journal:  Prog Lipid Res       Date:  2020-08-11       Impact factor: 16.195

5.  Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.

Authors:  Naoyuki Fujimori; Takeji Umemura; Takefumi Kimura; Naoki Tanaka; Ayumi Sugiura; Tomoo Yamazaki; Satoru Joshita; Michiharu Komatsu; Yoko Usami; Kenji Sano; Koji Igarashi; Akihiro Matsumoto; Eiji Tanaka
Journal:  World J Gastroenterol       Date:  2018-03-21       Impact factor: 5.742

6.  Lysophosphatidic acid reverses Temsirolimus-induced changes in lipid droplets and mitochondrial networks in renal cancer cells.

Authors:  Ravneet Chhabra; Meera Nanjundan
Journal:  PLoS One       Date:  2020-06-03       Impact factor: 3.240

7.  Possible involvement of TGF‑β‑SMAD‑mediated epithelial‑mesenchymal transition in pro‑metastatic property of PAX6.

Authors:  Meng Jin; Daili Gao; Rongchun Wang; Attila Sik; Kechun Liu
Journal:  Oncol Rep       Date:  2020-06-11       Impact factor: 3.906

8.  Activation of Autophagy Relieves Linoleic Acid-Induced Inflammation in Large Yellow Croaker (Larimichthys crocea).

Authors:  Bo Yang; Renlei Ji; Xueshan Li; Wei Fang; Qiuchi Chen; Qiang Chen; Wei Xu; Kangsen Mai; Qinghui Ai
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

9.  Autotaxin upregulated by STAT3 activation contributes to invasion in pancreatic neuroendocrine neoplasms.

Authors:  Linfei Yang; Xiao Yu; Yongchao Yang
Journal:  Endocr Connect       Date:  2018-12-01       Impact factor: 3.335

Review 10.  MicroRNA Regulation of the Autotaxin-Lysophosphatidic Acid Signaling Axis.

Authors:  Mandi M Murph
Journal:  Cancers (Basel)       Date:  2019-09-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.